#USA #Anixa Biosciences #San Jose #Breast Cancer #vaccine

Anixa Biosciences Secures Significant U.S. Patent for Breast Cancer Vaccine Technology

Anixa Biosciences, Inc., a notable player in the biotechnology arena, is on track to bolster its innovative breast cancer vaccine initiative with the acquisition of a crucial U.S. patent, scheduled for issuance on November 18, 2025. This patent, numbered 12,472,205, will substantially extend the company’s intellectual property rights, pushing them into the 2040s. This advancement not only strengthens Anixa's competitive stance but also underlines the company’s commitment to pioneering solutions for breast cancer, a disease projected to impact nearly 300,000 women in the United States alone in the coming year.

The patent covers groundbreaking techniques for eliciting a robust immune response against the α-lactalbumin protein. Typically associated with breast tissue during lactation, this protein has emerged as a promising target in the development of immunopreventive strategies aimed at breast cancer. Notably, Dr. Vincent Tuohy and Dr. Justin Johnson of Cleveland Clinic are credited as co-inventors of this patent.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, remarked, “Our breast cancer vaccine program is integral to our strategy in advancing next-generation preventive immunotherapies.” He noted that this patent not only extends the duration of their intellectual property protection but also emphasizes the company’s dedication to tackling a condition that affects hundreds of thousands of women annually. With a robust and expanding global patent portfolio, Anixa is poised to advance a vaccine that could radically alter the prevention paradigm for breast cancer among women.

The breast cancer vaccine developed in collaboration with Cleveland Clinic introduces an innovative perspective on prevention and treatment, reflecting a commitment to changing how we approach this widespread disease. This patent issuance reinforces the foundational patent protection for Anixa's breast cancer vaccine program into the mid-2040s, enhancing investor appeal and positioning.

Despite the strides made in treating breast cancer over recent years, it continues to be the most commonly diagnosed cancer among women worldwide. In the United States alone, the anticipated 297,000 new cases of invasive breast cancer for 2025 highlight the immediate need for preventive measures. Tragically, around 43,000 women are expected to succumb to the disease annually, illustrating the urgency behind such innovative initiatives. Currently, there are no FDA-approved vaccines intended for breast cancer prevention, representing a significant and unmet requirement in the realm of preventive oncology.

The investigational vaccine from Anixa aims to trigger the immune system to identify and destroy malignant cells that produce α-lactalbumin while preserving normal cells. By concentrating on this “retired” protein, which is largely absent in healthy tissues except during lactation, the vaccine promises to minimize unintended side effects while offering long-lasting immune defense.

About Anixa Biosciences

Anixa is an emerging player in the clinical-stage biotechnology sector, primarily focusing on cancer treatment and prevention. Their diverse therapeutic portfolio includes a collaborative ovarian cancer immunotherapy program with Moffitt Cancer Center. This program utilizes a novel CAR-T approach known as chimeric endocrine receptor-T cell (CER-T) technology. This innovative method differentiates itself by binding the natural ligand of the FSH receptor—FSH—directly to the receptor on tumor cells instead of using a fragment from an antibody. Moffitt Cancer Center stands at the forefront of cancer immunotherapy, paving the way for next-generation therapies, including CAR-T and tumor-infiltrating lymphocytes (TILs), to empower the immune system.

Anixa's collaborative vaccine development with Cleveland Clinic aims to tackle both breast and ovarian cancer, alongside efforts to create vaccines targeting various challenging malignancies such as lung, colon, and prostate cancers. These vaccine technologies pivot on the immunization against “retired” proteins found expressed in specific cancer types. With exclusive licenses from these institutions, Anixa’s model fosters synergy that allows for continuous exploration of emerging technologies across compatible fields for further development.

To keep abreast of Anixa’s developments, or to explore further details, visit www.anixa.com and follow them on LinkedIn, X, Facebook, and YouTube.